Purchase Order W81K0225PA043
Award Date 7/21/25
Potential Completion Date 9/30/25
Potential Value $116K
Funding Federal Agency
Contracting Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92122, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This firm fixed-price purchase order was awarded by the Defense Health Agency to Illumina, Inc., a manufacturer of genomic sequencing systems and reagents, for the procurement of Urinary Pathogen ID/AMR Enrichment Kits. The $61,848.39 contract has a period of performance through September 30, 2024 and will support the use of government-owned Illumina MiSeq sequencing instruments at Tripler Army Medical Center in Hawaii. The award was made on a sole source basis under the simplified acquisition...
- The Defense Health Agency, through the Medical Readiness Contracting Office - Pacific, awarded a $92,739.16 firm fixed price purchase order to Illumina, Inc. for Urinary Pathogen Identification/Antimicrobial Resistance (ID/AMR) Enrichment Kits to support diagnostic operations at Tripler Army Medical Center in Hawaii. This sole source award, made under FAR 13.106-1(b)(1), procures specialized diagnostic kits designed specifically for use with Government-Owned Illumina MiSeq sequencing systems....
- This firm fixed-price purchase order was awarded by the Department of the Army Medical Command to Illumina, Inc., a for-profit manufacturer of genetic sequencing systems and reagents. The $144,074.38 contract is for Illumina RNA prep with enrichment supplies to support the MiSeq system used at the Tripler Army Medical Center in Hawaii. The award was made on a sole-source basis without a set-aside, citing Illumina as the only responsible source for the proprietary sequencing technology....
- The Defense Health Agency awarded a $166,995 firm fixed-price purchase order to Illumina, Inc. for a five-year NextSeq 1000 Silver Support Plan effective through June 15, 2026. The contract will be performed at Tripler Army Medical Center in Honolulu, Hawaii. This support plan encompasses maintenance and technical support services for the NextSeq 1000 sequencing instrument, which is a mid-throughput genetic sequencing platform used for genomic research and analysis applications. No set-aside...
- The Defense Health Agency awarded a firm fixed-price purchase order to Illumina, Inc. on June 20, 2025, valued at $24,291.59, for deoxyribonucleic acid (DNA) sequencing reagent kits and Illumina DNA testing equipment designated for Walter Reed Medical Center in Bethesda, Maryland. The contract carries no set-aside designation, reflecting Illumina's specialized capabilities in genomic sequencing technologies. The purchase order is scheduled for completion by August 1, 2025, and represents a...
- The Department of the Army Medical Command awarded a $247,627.76 firm fixed-price purchase order to Illumina, Inc., a for-profit manufacturing organization, for Illumina RNA Prep with Enrichment products and services. The contract does not have a set-aside designation. This award was made without full and open competition under the sole-source authority of FAR 13.106-1(b)(1)(i) based on Illumina's proprietary sequencing technology and status as the sole manufacturer. Illumina has a history of...
- The U.S. Defense Health Agency awarded a firm fixed price Blanket Purchase Agreement (BPA) call to Illumina, Inc., a for-profit manufacturer of genetic sequencing instruments and reagents, to provide MiSeq Reagent Kits for $129,820.35. This award, which has no set-aside designation, supports the agency's ongoing requirements for nucleic acid sequencing capabilities. Illumina has previously received prime federal contracts from agencies like the National Institutes of Health, Centers for...
- This firm-fixed-price delivery order was awarded by the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Illumina, Inc., a for-profit manufacturer of genomic sequencing systems and reagents. The $14,995.63 contract is for the provision of Illumina's TruSeq brand sequencing kits, to be performed in San Diego, California. The award has no set-aside designation. Illumina has previously received prime contracts from various federal agencies, including...
- This is a firm fixed-price purchase order awarded by the Defense Health Agency (DHA) to Illumina, Inc. for next-generation sequencing (NGS) reagents to provide high-resolution human leukocyte antigen (HLA) typing for transplant recipients and donors. The $22,467.76 contract has a completion date of June 12, 2024. Illumina, a manufacturer of sequencing and genomic analysis instruments and reagents, has a history of providing sequencing systems and related products to support genomic research...
- Illumina, Inc. has been awarded a Blanket Purchase Agreement (BPA) call valued at $668,201.76 by the Defense Health Agency for the provision of reagents and service support plans. The award, executed on September 12, 2024, is structured as a firm fixed price contract with an ultimate completion date of September 30, 2025. Work will be performed at the contractor's facility in Takoma Park, Maryland. The contract was awarded without set-aside designation, reflecting Illumina's specialized...